Viewing Study NCT05199051

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:51 PM
Ignite Modification Date: 2026-02-23 @ 1:11 AM
Study NCT ID: NCT05199051
Status: RECRUITING
Last Update Posted: 2025-02-19
First Post: 2021-11-12
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD Relapse/refractory (R/R) AML
Sponsor: Centre Antoine Lacassagne
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None AML View
Keywords:

Keywords

Keyword Brief Keyword Text View
None AML View
None Gemtuzumab Ozogamicin Gilteritinib Combination View
None relapse View
None refractory View